Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or ImmunityBio, Inc.

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Alnylam Pharmaceuticals, Inc. and ImmunityBio, Inc. have taken different paths in optimizing these costs over the past decade.

Alnylam Pharmaceuticals, Inc.

From 2014 to 2023, Alnylam Pharmaceuticals saw a significant increase in SG&A expenses, growing by approximately 1,700%. This reflects their aggressive expansion strategy, focusing on scaling operations and market reach. By 2023, their SG&A expenses peaked, indicating a robust investment in administrative capabilities.

ImmunityBio, Inc.

Conversely, ImmunityBio, Inc. maintained a more conservative approach, with SG&A expenses increasing by about 2,900% from 2014 to 2023. Their strategy appears to focus on lean operations, optimizing costs while still supporting growth.

Both companies showcase distinct strategies in managing SG&A costs, reflecting their unique business models and market strategies.